Ovarian cancer symptoms are real, but they are also ordinary: bloating, feeling full after a few bites, pelvic or abdominal pain, and needing to urinate more often. Almost every woman has felt at least one of them, which is exactly why this cancer is often found late. The signal is not the symptom itself but its pattern — new, persistent and frequent. In this article you will learn which changes deserve an appointment, why the CA-125 blood test is not a screening test for average-risk women even though it is constantly asked for, how doctors actually confirm or rule out the disease, and what modern treatment looks like. Most women with these complaints do not have cancer, and knowing the real rules helps you act on evidence rather than fear.
What ovarian cancer is, and where it actually starts
Ovarian cancer is a group of diseases in which cells in or near the ovaries grow out of control. The ovaries are two almond-sized organs deep in the pelvis, on either side of the uterus, that release eggs and produce most of a woman’s estrogen and progesterone. Because they sit behind the bowel and bladder, a tumor can grow to a surprising size before it presses on anything a person can clearly feel.
The main types
Roughly nine out of ten cases are epithelial, arising from surface-lining cells, and high-grade serous carcinoma is by far the most common and most aggressive subtype within that group. Two rarer families exist: germ cell tumors, which appear in young women and are often highly curable, and stromal tumors, which come from hormone-producing tissue and are frequently caught early because they disturb hormone levels.
Why the fallopian tube matters
One of the most important shifts in gynecologic medicine is the recognition that most high-grade serous cancers do not begin in the ovary at all. They begin at the fimbrial end of the fallopian tube — the fringed opening that reaches toward the ovary — and shed cells onto the ovarian surface and into the abdomen. That explains why removing the tubes during another planned pelvic operation is now discussed as prevention, and why disease can spread before the ovary looks abnormal on a scan.
Ovarian cancer symptoms: real, but easy to dismiss
The old description of ovarian cancer as a silent disease is inaccurate: most women do report symptoms before diagnosis. The problem is that those symptoms overlap almost perfectly with irritable bowel syndrome, perimenopause, food intolerance and ordinary stress. What separates them is the pattern, not the sensation.
The four core symptoms
Four ovarian cancer symptoms show up repeatedly in women who are later diagnosed: abdominal bloating or a visible increase in abdominal size, feeling full very quickly when eating, pelvic or abdominal pain, and urinary urgency or frequency. Others appear less consistently: fatigue, back pain, constipation, pain during sex, and unexplained weight loss. Vaginal bleeding after menopause sits in a category of its own and should never be watched and waited on.
The threshold that actually matters
The US Centers for Disease Control and Prevention gives a concrete rule rather than a vague warning: if you have these signs for two weeks or longer and they are not normal for you, see a doctor, and if you have unusual vaginal bleeding, see a doctor right away. Clinicians look for three features together — the symptom is new to you, it happens on most days, and it has lasted weeks rather than years. Bloating you have had every summer for a decade behaves differently from bloating that started six weeks ago.
| Symptom | Usually not concerning when | Worth an appointment when |
|---|---|---|
| Bloating or larger abdomen | It comes and goes with meals, cycle or stress and has done so for years | It is new, present most days for two weeks or more, and clothes fit differently |
| Feeling full quickly | It follows a large or rich meal | Small portions now feel like too much, most days, for two weeks or more |
| Pelvic or abdominal pain | It is cyclical and matches a known pattern such as period pain | It is new, persistent and does not track your cycle |
| Urinary urgency or frequency | It follows caffeine, extra fluids or a treated infection | It persists with no infection found and no obvious trigger |
| Vaginal bleeding after menopause | Never — this is always worth evaluating | Immediately, without waiting two weeks |
None of this means cancer. Bloating and pelvic pain are far more often caused by benign conditions, and one of the most frequent is endometriosis. We also publish a full guide to endometriosis symptoms and treatment. The point is that a pattern lasting two weeks deserves a conversation, not a search engine.
The CA-125 truth: what this blood test can and cannot do
Women routinely ask their doctor for a CA-125 test to check for ovarian cancer. It is one of the most reasonable-sounding requests in medicine, and one of the most misunderstood. CA-125 is a protein shed by many cells that line body cavities. Ovarian cancer cells often produce a lot of it — but so do a great many harmless things.
Why it is not a screening test
Screening means testing people who feel completely well in order to catch disease early. For CA-125 that fails on two fronts. The level is normal in a substantial share of early-stage ovarian cancers, so a reassuring number does not mean the ovaries are clear. And it is raised in so many non-cancerous situations that most abnormal results in healthy women are false alarms, each of which can lead to imaging, anxiety and sometimes surgery on a woman who never had cancer.
This is not a matter of opinion. The largest randomized screening study ever run tested annual CA-125 with ultrasound follow-up in more than two hundred thousand postmenopausal women. It found more cancers at an earlier stage, yet after long-term follow-up it did not reduce deaths from the disease. On that evidence the US Preventive Services Task Force recommendation on ovarian cancer screening advises against screening asymptomatic women without a known high-risk hereditary syndrome. The CDC puts it plainly: there is no reliable way to screen for ovarian cancer in women who have no symptoms, and the Pap test does not screen for it either.
What else raises CA-125
| Common non-cancer cause of a raised CA-125 | Why it happens |
|---|---|
| Endometriosis | Irritated tissue in the pelvis releases the same protein |
| Uterine fibroids | Benign muscle growths inflame the surrounding lining |
| Pelvic inflammatory disease | Infection inflames the tubes and pelvic surfaces |
| Menstruation | Normal cycling of the uterine lining raises the level temporarily |
| Pregnancy | Placental and uterine tissue produce it |
| Liver disease and fluid in the abdomen | Irritation of the abdominal lining increases release |
Because of that list, a single elevated value in a premenopausal woman is a weak signal on its own. Readers making sense of a report they already have can consult a plain-language explanation of CA 125 test results.
Where CA-125 genuinely earns its place
The test has two solid jobs. It monitors known disease: once ovarian cancer is diagnosed, the trend of CA-125 over time tracks how well treatment is working and can flag a recurrence. And it helps assess a pelvic mass already found on imaging, where the level is read alongside the ultrasound appearance and menopausal status. A narrower third role exists in surveillance for women carrying a known high-risk mutation. In younger women with a suspected germ cell tumor, doctors instead order the hCG blood test, the AFP blood test and the LDH blood test.
Risk factors, genes, and why testing everyone diagnosed matters
Most women who develop ovarian cancer have no obvious risk factor beyond age. Risk climbs after 50 and is highest after menopause, which is one reason new pelvic symptoms at this stage of life are taken seriously; readers in that transition can also consult the symptoms and stages of menopause.
BRCA1, BRCA2 and Lynch syndrome
Inherited changes in the BRCA1 and BRCA2 genes are the strongest known risk factors. These genes normally help repair broken DNA; when one copy is faulty from birth, cells accumulate damage more easily. Carriers face a substantially higher lifetime risk of ovarian, fallopian tube and breast cancer, which is why the two conditions cluster in families. Our companion article covers breast cancer symptoms and treatment. Lynch syndrome, better known for raising colorectal and uterine cancer risk, also raises ovarian risk and is worth asking about when several cancers run in a family.
Why genetic testing is offered to everyone diagnosed
US practice now recommends germline genetic testing for every woman diagnosed with epithelial ovarian cancer, regardless of age or family history, for two reasons. The result changes treatment, because tumors with faulty DNA repair respond particularly well to a class of drugs discussed below. And it changes the family, because a confirmed mutation lets sisters, daughters and mothers be tested and consider risk-reducing surgery or closer surveillance.
Other factors that shift the odds
Risk is modestly higher with endometriosis, obesity, never having been pregnant, early periods or late menopause, and long-term postmenopausal hormone therapy. It is modestly lower with pregnancy and breastfeeding, several years of combined oral contraceptive use, and tubal surgery. These are population tendencies, not predictions.
How ovarian cancer is actually diagnosed
When ovarian cancer symptoms persist, there is still no single test that says yes or no. Diagnosis is a sequence, and knowing it removes a lot of uncertainty.
The pathway, step by step
- A clinical assessment, including a pelvic examination, to characterize the symptoms and feel for a mass.
- Transvaginal ultrasound, the first-line imaging test, which shows the ovaries and describes any mass — its size, whether it is fluid-filled or solid, and how much blood flow it has.
- Blood work. Doctors usually order CA-125 together with a complete blood count panel, then add kidney and liver chemistry that includes an albumin blood level.
- Cross-sectional imaging with CT of the abdomen and pelvis if the mass looks concerning, to look for spread and plan surgery.
- Surgery, both the definitive diagnostic step and the first treatment, since only tissue examined under a microscope confirms the diagnosis and its subtype.
Advanced disease can also lower red cell counts, which is why some women reach these tests only after a doctor first identifies iron deficiency anemia.
Why the surgeon matters
If imaging and blood tests suggest a mass may be malignant, the operation should be planned and performed by a gynecologic oncologist — a surgeon trained specifically in cancers of the female reproductive organs. The CDC guidance on ovarian cancer treatment tells women to ask for that referral, and outcomes are consistently better when the first operation is complete and correctly staged.
Staging
Stage is decided during surgery, not before it. Stage I is confined to one or both ovaries or tubes; stage II has spread within the pelvis; stage III, the most common stage at diagnosis, involves the abdominal lining or lymph nodes; stage IV has reached distant organs such as the liver or lungs. Stage guides treatment intensity, but it does not decide any individual’s story.
Treatment: surgery, chemotherapy and targeted drugs
Surgery and chemotherapy
Standard treatment combines cytoreductive surgery — removing as much visible tumor as possible, usually including the ovaries, tubes, uterus and the fatty apron of tissue called the omentum — with platinum-based chemotherapy, most often carboplatin and paclitaxel. When disease is extensive, chemotherapy may be given first, then continued after surgery. Younger women with early-stage disease of a favorable subtype can sometimes keep one ovary and the uterus to preserve fertility.
PARP inhibitors and HRD testing
The biggest change of the last decade is maintenance treatment with PARP inhibitors — drugs such as olaparib, niraparib and rucaparib that block a backup DNA repair pathway. Cancer cells with faulty repair machinery, including those with BRCA mutations, lean heavily on that backup; take it away and the cell cannot survive. Tumors are therefore tested for homologous recombination deficiency, or HRD, a laboratory description of that repair weakness. Women whose tumors show HRD gain the most, which is why the test now shapes the treatment plan.
Follow-up and monitoring
After treatment, follow-up combines clinical review, imaging when indicated, and CA-125 measurement in women whose level was raised at diagnosis. Here the marker does its real job, since a rising trend in someone with known disease means something quite different from a single number in a healthy woman.
When to see a doctor
Ovarian cancer symptoms overlap with dozens of harmless conditions, so use a decision path rather than an open-ended list.
- Unusual vaginal bleeding, especially after menopause: contact a doctor now, without waiting.
- Bloating, early fullness, pelvic pain or urinary urgency that is new for you and present on most days for two weeks or longer: book an appointment and describe the pattern, not just the symptom.
- A first-degree relative with ovarian, fallopian tube, peritoneal or early breast cancer, or a known BRCA or Lynch mutation in the family: ask for a referral to genetic counseling even if you feel completely well.
- Sudden severe pelvic pain, vomiting, or an abdomen that swells rapidly over days: seek urgent care, as this can signal a twisted ovary or fluid buildup.
- A pelvic mass already found on a scan: ask specifically whether a gynecologic oncologist should review it before any surgery is scheduled.
When you go, bring dates: saying that something started in early June and happens most days gives a clinician far more to work with than a vague report of recent bloating.
Latest scientific advances
Research has moved quickly, but not always in the direction people expect. Here is what recent work actually shows.
Screening still does not save lives at average risk
The largest randomized trial of ovarian cancer screening ever run followed more than two hundred thousand postmenopausal women with annual CA-125 tests and ultrasound follow-up. It did shift some cancers to an earlier stage, but over long-term follow-up it did not reduce deaths. A 2024 review reached the same conclusion across all the randomized evidence. What this means for you: if you feel well and have no inherited high-risk condition, a routine yearly CA-125 is not a shortcut to safety, and a normal result should not stop you reporting new ovarian cancer symptoms later.
The fallopian tube is now the prevention target
A 2024 review of the global epidemiology of ovarian cancer confirmed that most high-grade serous cancers begin in the fallopian tube, and argued that removing the tubes during another planned operation is a genuine prevention opportunity. A large Canadian study comparing tens of thousands of women who had their tubes removed with matched women who did not has not yet shown a clear drop in cancers, but the researchers noted that too few cases had occurred and follow-up was too short to judge. This remains preliminary. What this means for you: if you are already scheduled for a hysterectomy or permanent contraception, it is reasonable to ask your surgeon whether removing the tubes is appropriate in your case.
Targeted maintenance drugs work best when the tumor is tested
Two large international trials reported final survival results recently. In one, adding niraparib as maintenance after first-line chemotherapy clearly delayed the cancer’s return, but the final analysis did not show that women lived longer overall. In the other, combining olaparib with bevacizumab gave a meaningful survival advantage specifically to women whose tumors showed homologous recombination deficiency, while women without that feature did not gain in the same way. What this means for you: asking whether a tumor has been tested for HRD and for BRCA changes is a practical question, because the answer can decide which maintenance drug is worth taking.
Resistance is the next problem being worked on
A 2025 review examined why PARP inhibitors eventually stop working in many women who initially respond, mapping the escape routes cancer cells use to restore DNA repair. No new treatment has come from it yet. What this means for you: it explains why oncologists monitor treatment closely and change plans when a marker or scan starts moving, and why clinical trials are worth discussing rather than saving as a last resort.
Glossary
| Term | Definition |
|---|---|
| Adnexal mass | A lump found in the region of the ovary or fallopian tube. Most are benign cysts, but the description on ultrasound guides what happens next. |
| Ascites | Fluid that collects in the abdomen, causing swelling and a feeling of pressure. It has many causes, including liver disease and advanced cancer. |
| BRCA1 and BRCA2 | Two genes that help repair damaged DNA. Inherited faults in either gene raise the lifetime risk of ovarian, fallopian tube and breast cancer. |
| CA-125 | Cancer antigen 125, a protein measured in blood. Useful for monitoring known ovarian cancer and assessing a pelvic mass, not for screening healthy women. |
| Cytoreductive surgery | Also called debulking surgery. An operation to remove as much visible tumor as possible, which improves how well chemotherapy works afterward. |
| Gynecologic oncologist | A surgeon with additional training in cancers of the female reproductive organs, including ovarian, uterine and cervical cancer. |
| High-grade serous carcinoma | The most common and most aggressive subtype of epithelial ovarian cancer. Most cases are now thought to begin in the fallopian tube. |
| Homologous recombination deficiency | Shortened to HRD. A laboratory finding that a tumor cannot repair DNA breaks properly, which makes it more sensitive to platinum chemotherapy and PARP inhibitors. |
| Lynch syndrome | An inherited condition that raises the risk of colorectal, uterine and ovarian cancer, caused by faults in genes that correct DNA copying errors. |
| Transvaginal ultrasound | A scan performed with a slim probe placed in the vagina, giving a close, detailed view of the ovaries, tubes and uterus. |
Frequently asked questions
Can a Pap smear detect ovarian cancer?
No. A Pap test samples cells from the cervix and is designed to find cervical cell changes caused by human papillomavirus. It does not reach the ovaries or fallopian tubes, and the CDC states plainly that the Pap test does not screen for ovarian cancer. This is one of the most common and most consequential misunderstandings in women’s health, because a normal Pap result can create false reassurance. A woman with normal Pap results and persistent new bloating, early fullness or pelvic pain still needs those symptoms evaluated on their own terms.
Can a routine blood test or a complete blood count detect ovarian cancer?
Not directly. A complete blood count measures red cells, white cells and platelets, and none of those values identifies ovarian cancer. It can show indirect clues, such as anemia from chronic bleeding or a high platelet count that sometimes accompanies advanced disease, but those findings are non-specific and appear in many conditions. Standard chemistry panels behave the same way. Blood tests support a diagnosis; they do not make one. Imaging and, ultimately, tissue examined under a microscope are what confirm ovarian cancer.
How can I check for ovarian cancer at home?
There is no reliable home test or self-examination for ovarian cancer, and no supplement, diet or at-home kit changes that. The ovaries sit too deep in the pelvis to be felt through the abdominal wall in most women. What you can usefully do at home is track patterns: note when a symptom started, how many days a week it occurs, and whether it is changing. That written record is genuinely useful to a clinician and is the closest thing to a meaningful home check.
Can an ultrasound detect ovarian cancer?
Transvaginal ultrasound is the best first imaging test and can show an ovarian mass and describe features that suggest concern, such as solid areas, thick internal walls or increased blood flow. It cannot, however, prove that a mass is cancerous. Many masses it finds are benign cysts that resolve on their own. Ultrasound findings are combined with symptoms, menopausal status and blood results to decide whether further imaging or surgery is needed, and only tissue analysis gives a definite answer.
What were the first symptoms in most women who were diagnosed?
Looking back, most women describe something ordinary that would not stop: bloating that made waistbands tight, feeling full after a few mouthfuls, a dull pelvic ache, or needing the bathroom more often. Fatigue and back pain are frequently mentioned too. Very few describe a dramatic event. This is precisely why the pattern rule matters more than the symptom list. A symptom that is new for you and present on most days for two weeks or longer deserves an appointment, whatever it happens to be.
Is ovarian cancer curable?
Many women are cured, particularly when the disease is found while it is still confined to the ovary or tube, and outcomes at that stage are generally very good. Advanced disease is harder, and it frequently returns after initial treatment, but it is increasingly treated as a condition that can be controlled over years rather than a single event. Surgery quality, platinum chemotherapy and maintenance therapy guided by genetic testing have all improved the outlook. Prognosis depends on stage, subtype, genetic features and overall health, and only your oncology team can put those pieces together for you.
Sources
- Centers for Disease Control and Prevention — Screening for Ovarian Cancer, 2024 — CDC ovarian cancer screening guidance
- MedlinePlus, National Library of Medicine — CA-125 Blood Test (Ovarian Cancer), 2024 — MedlinePlus CA-125 blood test page
- Mayo Clinic — Ovarian cancer: symptoms and causes, 2024 — Mayo Clinic ovarian cancer overview
- Menon U, Gentry-Maharaj A, Burnell M, et al. — Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial — The Lancet, 2021 — read the UKCTOCS long-term mortality results
- Sideris M, Menon U, Manchanda R — Screening and prevention of ovarian cancer — Medical Journal of Australia, 2024 — read the review of ovarian cancer screening and prevention
- Webb PM, Jordan SJ — Global epidemiology of epithelial ovarian cancer — Nature Reviews Clinical Oncology, 2024 — read the review of epithelial ovarian cancer epidemiology
- Giannakeas V, Murji A, Lipscombe LL, Narod SA, Kotsopoulos J — Salpingectomy and the Risk of Ovarian Cancer in Ontario — JAMA Network Open, 2023 — read the Ontario salpingectomy cohort study
- Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. — Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial — Annals of Oncology, 2024 — read the PRIMA final survival results
- Ray-Coquard I, Leary A, Pignata S, et al. — Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial — Annals of Oncology, 2023 — read the PAOLA-1 final survival results
- Kulkarni S, Seneviratne N, Tosun C, et al. — PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy — DNA Repair, 2025 — read the review of PARP inhibitor resistance
Further reading
- Compare a related tumor marker by opening the guide to CA 15-3 blood test results.
- See what a genuinely effective screening program looks like by reading the guide to colorectal cancer symptoms and treatment.
- Review another cancer that is often found late by opening the guide to pancreatic cancer symptoms and treatment.
- Understand the main hormone produced by the ovaries by reading the guide to estradiol blood test results.
- Track kidney function during chemotherapy by consulting the guide to creatinine test results.
Understand your lab results with BloodSense
A pelvic symptom rarely comes with a single clean answer, and the reports that follow it — a CA-125 value, a complete blood count, liver and kidney chemistry, sometimes hormone levels — are easy to misread on your own. BloodSense reads those reports with you, explaining what each value means, which results sit outside the usual range and which questions are worth raising at your next appointment. It helps you understand your results; it does not diagnose, and it does not replace your doctor or your gynecologic team.
